Skip to main content
Find Eczema-Friendly ProductsFind a Doctor
Logo
search
menu
About Eczema
Research
News & Stories
Get Involved
About Us
Donate
post image
Press Releases

FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

November 30, 2023National Eczema Association
  1. Home
  2. Blog
  3. FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
Toggle drawer

Get the latest in eczema news, delivered.

Sign up for NEA's e-newsletter to receive evidence-based articles, expert-sourced lifestyle tips and stories from your community.

Nea footer logo
  • About NEA
  • Press Room
  • Contact Us
  • Careers
  • Seal of Acceptance Application
  • Partnership Opportunities
  • Annual Report and 990
  • Privacy Policy
  • Terms and Conditions
facebookXyoutubesocial iconthreadslinked-in

The National Eczema Association (NEA) improves the health and quality of life for people affected by eczema, and empowers those who advocate, support and deliver care.

Our Accreditations

National Health Council standards of excellence certification programGuide Star Seal of TransparencyBetter Business Bureau accredited charityGlobal Skin internation alliance of dermatology patient organizationsaccreditation logo

NEA is a qualified 501(c)(3) EIN 93-0988840.

© National Eczema Association, All rights reserved 2026